Clinical Research Directory
Browse clinical research sites, groups, and studies.
Clinical Study of the Safety of Menhycia® in 3-Month-Old Infants
Sponsor: CanSino Biologics Inc.
Summary
This study is an open, multicenter Phase IV clinical study to evaluate the safety of vaccination with Menhycia®. The study plan is to enroll approximately 3,000 infants at 3 months of age who have not been vaccinated with any epidemic encephalitis vaccine, and to administer a total of 3 doses of Menhycia®, with a minimum of 1 month between doses, and a booster dose of 1 dose of immunization is allowed at 12 months of age.
Official title: Phase IV Clinical Study of the Safety of Menhycia® in 3-Month-Old Infants
Key Details
Gender
All
Age Range
3 Months - 3 Months
Study Type
INTERVENTIONAL
Enrollment
3011
Start Date
2024-06-12
Completion Date
2025-12
Last Updated
2025-08-15
Healthy Volunteers
Yes
Conditions
Interventions
MCV4
4 doses of vaccine on Day 0, Day30, Day 60 and Month 12
Locations (1)
Nanjing Luhe District Center for Disease Control and Prevention Center for Disease Control and Prevention
Nanjing, China